Cole, Jeremy
Cąpała-Szczurko, Iwona
Roseti, Stephanie http://orcid.org/0000-0003-1217-393X
Chen, Claudia
Caveney, Scott http://orcid.org/0000-0002-2006-5130
Aksyuk, Anastasia A.
Streicher, Katie
Ponnarambil, Sandhia
Colice, Gene
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study
https://doi.org/10.1007/s41030-023-00245-9
Funding for this research was provided by:
AstraZeneca United States
Amgen
Article History
Received: 4 October 2023
Accepted: 6 November 2023
First Online: 8 December 2023
Declarations
:
: These results were previously presented at the CHEST Annual Meeting, 8–11 October 2023, Honolulu, HI, USA.
: Jeremy Cole has nothing to declare. Iwona Cąpała-Szczurko, Stephanie Roseti, Claudia Chen, Anastasia A Aksyuk, Katie Streicher, and Sandhia Ponnarambil are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Scott Caveney is an employee of Amgen and owns stock in Amgen. Gene Colice was an employee of AstraZeneca at the time of the study.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation good clinical practice guidelines, and applicable regulatory requirements. Approvals from the central institutional review board (Advarra, Columbia, MD, USA) and local independent ethics committees were obtained, and all patients or their legal guardians provided written informed consent in accordance with local requirements.